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1. Introduction 
Tuberculosis (TB) caused by Mycobacterium tuberculosis continues being a big public health 
problem around the world. The total number of cases of TB worldwide in 2009 was 9.4 
million of which 1.8 million died of this disease, reported as the higher in history (Lawn & 
Zumla, 2011), World Health Organization (WHO) estimates that the one third of global 
population is infected latently by M. tuberculosis (LTBI), however 10% will develop active 
disease (Zumla et al., 2011). Although several strategies and programs have been 
implemented and anti TB drugs have been available for 50 years, many TB patients are not 
diagnosed and treated at time (Ghanashyam, 2011; Sosnik et al., 2010). These mismanaged 
patients, with non-optimal treatments are the principal source of multidrugresistant TB 
(MDR-TB), which is resistant to the first line drugs isoniazid and rifampicin, as well as 
extensive drug resistant TB (XDR-TB), that in addition of isoniazid and rifampicin is 
resistant to any fluoroquinolone and any aminoglycoside second line anti TB injectable 
drugs (Koul et al., 2011). Other aspect that aggravates the situation is the coinfection with 
Human Immunodeficiency Virus (HIV) disease, which increases the TB incidence rates three 
to five times and affected 1.1 million of TB cases in 2009 (Lawn & Zumla, 2011).  
The most important control measures in TB are the prevention and chemotherapy. The 
current TB therapy has difficulties in controlling effectively the disease, due to inadequate 
adherence to treatment course caused by the length of time of medication and adverse 
reactions (Ginsberg & Spigelman, 2007). New antitubercular drugs should comply with 
following characteristics with the aim of reduce the low adherence that induce therapeutic 
failure and resistance: be active against MDR and XDR isolates, be active in less time to 
shorten the therapy, not interact with antiviral drugs, effectivity against latent TB infection, 
low toxicity and high bioavailability (Mitchinson & Fourie, 2010; Sosnik et al., 2010). 
For those reasons the design of an antitubercular drug discovery initiative should have a 
strong in vitro screening program with the ability of optimize the current process and to 
identify in high degree chemical scaffolds with potent in vivo activity for clinical 
development. The aim of this chapter is offer different tools to perform a rational search for 
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1.1 Antitubercular drug resistance versus the discovery and development of new 
antitubercular agents  
The drug resistant TB (DR-TB) emergence and spread is a multifactorial problem produced 
by health mismanagement attention; inadequate therapy courses, antibiotic misuse, 
insufficient socioeconomic conditions, presence of immunodeficiency disorders and low 
patient compliance (Haydel, 2010). In addition, coinfection TB-VIH complicates the current 
treatment regimen because: decrease compliance and increase drug interactions producing 
toxic side effects (Koul et al., 2011). The need for more effective and less toxic anti TB drugs 
is really urgent, but the antibiotic drug discovery and development is a long and expensive 
process with very few compounds making it to the market (Vaddady et al., 2010). The 
current anti-TB drugs were developed since 1950s until 1980s which represented a missed 
period in TB drug research that contributed greatly to new challenges for improving 
treatments for DR-TB and prevent LTBI (Ginsberg, 2010). Actually, the biggest challenge for 
discover and develop a new era of TB medicines is prevention of drug resistance, which is 
necessary for treat the patients under ineffective therapeutic regimens (Ginsberg, 2010). 
Because of this, all efforts between sponsors, TB drug researchers, regulators and funders 
should be directed to the development of new and optimized portfolio of multidrug 
treatments. 
1.2 Antitubercular in vitro drug discovery program design 
In vitro experiments seeking to assess the interaction between the drug and the bacteria, 
which validates the selection of candidate compounds and the determination of the target 
drug concentrations for further testing (Vaddady et al., 2010). Is a fact that drug candidates 
fail in the stage of clinical development, in the Tuberculosis Antimicrobial Acquisition and 
Coordinating Facility Program (TAACF) were evaluated 88601 compounds and finally were 
selected five potential leads (Lenaerts et al., 2008), which is a high cost drug discovery 
program. An in vitro antitubercular drug screening strategy should consider and integrate 
several aspects as whole cell screening; single enzyme targets, toxicity testing and the 
inclusion of in vitro pharmacological tests for optimize the selection of promissory new 
drugs and predicts their clinical behaviour (Koul et al., 2011). In Fig. 1. is shown the design 
of an in vitro drug discovery program with the major phases looking for evaluate and 
select the largest possible number of novel antitubercular molecules.  
 
Fig. 1. In vitro anti TB drug discovery program components, each phase is an important step 
in the selection of promising anti TB drugs 
2. Screening methods  
In the 1950s, Canetti et al. described the first Drug Susceptibility Testing (DST) method for 
M. tuberculosis, which was a agar dilution method, involving the preparation of a 
concentration series of drugs against M. tuberculosis complex in Lowenstein-Jensen medium, 
inoculation of the bacterial cultures on the slants, and reading of the inhibition of growth by 
drugs at different concentrations (Canetti et al., 1963). The agar dilution tests permit to 
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